Literature DB >> 34188601

Atypical Neuroleptic Malignant Syndrome Induced by Low Dose Quetiapine in a Patient Treated with Donepezil.

Elçin Özçelik Eroğlu1, M İrem Yildiz1, M Kâzım Yazici1.   

Abstract

Neuroleptic malignant syndrome is a rare idiosyncratic drug reaction that causes morbidity and mortality. Although muscle rigidity and fever are accepted as major symptoms, there is no consensus on the diagnostic criteria. This flexibility in diagnostic criteria allows for the diagnosis of atypical cases. Keeping in mind that neuroleptic malignant syndrome may also occur with the use of low doses of atypical antipsychotics is important for making the diagnosis quickly and reducing the risk of morbidity and mortality. In this report, we aim to present a case with atypical neuroleptic malignant syndrome associated with the use of very low dose quetiapine and discuss the risk factors that facilitate its emergence. Copyright:
© 2021 Turkish Neuropsychiatric Society.

Entities:  

Keywords:  Quetiapine; antipsychotic agents; cholinesterase inhibitors; donepezil; neuroleptic malignant syndrome

Year:  2021        PMID: 34188601      PMCID: PMC8214739          DOI: 10.29399/npa.27421

Source DB:  PubMed          Journal:  Noro Psikiyatr Ars        ISSN: 1300-0667            Impact factor:   1.339


  16 in total

1.  Neuroleptic malignant syndrome induced by donepezil.

Authors:  T Matsumoto; C Kawanishi; D Isojima; E Iseki; I Kishida; K Kosaka
Journal:  Int J Neuropsychopharmacol       Date:  2004-01-20       Impact factor: 5.176

2.  [A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses].

Authors:  J DELAY; P PICHOT; T LEMPERIERE; B ELISSALDE; F PEIGNE
Journal:  Ann Med Psychol (Paris)       Date:  1960-01       Impact factor: 0.380

3.  Neuroleptic malignant syndrome: evaluation of drug safety data from the AMSP program during 1993-2015.

Authors:  Michael Schneider; Johannes Regente; Timo Greiner; Stephanie Lensky; Stefan Bleich; Sermin Toto; Renate Grohmann; Susanne Stübner; Martin Heinze
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-11-30       Impact factor: 5.270

4.  An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method.

Authors:  Ronald J Gurrera; Stanley N Caroff; Abigail Cohen; Brendan T Carroll; Francis DeRoos; Andrew Francis; Steven Frucht; Sanjay Gupta; James L Levenson; Ahsan Mahmood; Stephan C Mann; Michael A Policastro; Patricia I Rosebush; Henry Rosenberg; Perminder S Sachdev; Julian N Trollor; Varadaraj R Velamoor; Charles B Watson; Jayne R Wilkinson
Journal:  J Clin Psychiatry       Date:  2011-06-28       Impact factor: 4.384

5.  Case reports of neuroleptic malignant syndrome in context of quetiapine use.

Authors:  Mark B Detweiler; Kelly Sullivan; Taral R Sharma; Kye Y Kim; Jonna G Detweiler
Journal:  Psychiatr Q       Date:  2013-12

Review 6.  Neuroleptic malignant syndrome: A neuro-psychiatric emergency: Recognition, prevention, and management.

Authors:  Raj Velamoor
Journal:  Asian J Psychiatr       Date:  2017-05-04

Review 7.  Neuroleptic malignant syndrome associated with atypical antipsychotic drugs.

Authors:  Julian N Trollor; Xiaohua Chen; Perminder S Sachdev
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

8.  Atypical Neuroleptic Malignant Syndrome Precipitated by Clozapine and Quetiapine Overdose: A Diagnostic Challenge.

Authors:  David Choon Liang Teo; Hon Khuan Wong; Sheng Neng Tan
Journal:  Innov Clin Neurosci       Date:  2018-08-01

Review 9.  Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis.

Authors:  Martino Belvederi Murri; Argentina Guaglianone; Michele Bugliani; Pietro Calcagno; Matteo Respino; Gianluca Serafini; Marco Innamorati; Maurizio Pompili; Mario Amore
Journal:  Drugs R D       Date:  2015-03

10.  Delirium Induced by Quetiapine and the Potential Role of Norquetiapine.

Authors:  Filipe Almeida; Elisabete Albuquerque; Ilda Murta
Journal:  Front Neurosci       Date:  2019-08-20       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.